Specialty hub

Haematology

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Haematology.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Haematology is the branch of medicine that deals with disorders or abnormalities in the blood and connected areas such as blood cells, haemoglobin and blood vessels. Haematology also covers bone marrow and spleen, which are the blood producing organs.

Featured Learning Zones

Learning Zone Homepage

Fibrinogen Deficiency in Bleeding Learning Zone

Fibrinogen is an essential coagulation factor in the blood clotting cascade. The importance for fibrinogen in normal haemostasis is highlighted in patients of inherited fibrinogen deficiencies who display coagulopathies such as excessive bleeding and thrombolytic events.

Learning Zone Homepage

Oral Anticoagulation Reversal Learning Zone

This educational resource is designed to help healthcare professionals diagnose, manage and treat bleeding in patients taking anticoagulants.

Venous Thromboembolism (VTE) Learning Zone

Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE), and is associated with long-term complications, disability and significant mortality.

Learn more

Haematology focuses on the study, diagnosis, treatment, and prevention of diseases including coagulation and haemorrhagic disorders such as fibrinogen deficiency, haematological and bone marrow cancers such as leukaemia and lymphoma, and anaemia.

Diseases in this section

Coagulation and Haemorrhagic Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Haematological and Bone Marrow Cancers

Containing relevant Learning Zones, guidelines, trials and news.

HIV

Containing relevant Learning Zones, guidelines, trials and news.

Venous thromboembolism

Containing relevant Learning Zones, guidelines, trials and news.

Related news and insights

Drug news

European Commission grants conditional approval of Carvykti, for the treatment of patients with relapsed and refractory multiple myeloma.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) granted conditional marketing authorisation of Carvykti ( ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.

1 mins

Drug news

Sarclisa combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy.

Latest results from the Phase III IKEMA clinical trial evaluating Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival (mPFS) of 35.7 months (Hazard Ratio HR 0.58; 95% Confidence Interval CI: 25.8 to 44.0; n=179), compared to 19.2 months in patients treated with Kd alone (95% CI: 15.8 to 25.1; n=123), as evaluated by an Independent Review Committee.

1 min

Drug news

FDA lifts clinical hold on investigational lenacapavir for the treatment and prevention of HIV.

Gilead Sciences, Inc. announced the FDA has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP).

1 min

See all news

Related Drugs

Tranexamic acid 100 mg/ml solution for injection

1 mins

Deferasirox Zentiva 90 mg film-coated tablets

1 mins

Deferasirox Zentiva 360 mg film-coated tablets

1 mins

Deferasirox Zentiva 180 mg film-coated tablets

1 mins

Deferasirox Sandoz 90 mg film-coated tablets

1 mins

Deferasirox Sandoz 360 mg film-coated tablets

1 mins

Deferasirox Sandoz 180 mg film-coated tablets

1 mins

Deferasirox Mylan 90 mg, 180 mg, and 360 mg Film-coated Tablets

1 mins

Deferasirox Dr. Reddys 90 mg Film-Coated Tablets

1 mins

Deferasirox Accord 90 mg film-coated tablets

1 mins

Deferasirox Accord 360 mg film-coated tablets

1 mins

Deferasirox Accord 180 mg film-coated tablets

1 mins

Deferasirox 90mg Film-Coated Tablets

1 mins

Deferasirox 360mg Film-Coated Tablets

1 mins

Deferasirox 180mg Film-Coated Tablets

1 mins

Related Journals

Journal

Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report

2 mins

Journal

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

2 mins

Journal

Distinct viral reservoirs in individuals with spontaneous control of HIV-1

1 mins

Journal

Recent Advances in the Development of Integrase Inhibitors for HIV Treatment

1 mins

Journal

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

1 mins

Journal

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

1 mins

Journal

Advances toward Curing HIV-1 Infection in Tissue Reservoirs

1 mins

Journal

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety

1 mins

Journal

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

1 mins

Journal

Dolutegravir plus lamivudine for the treatment of HIV-1 infection

1 mins

Related Guidelines

Guideline

BHIVA guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update)

The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of women living with HIV in the UK during pregnancy and postpartum, and their infants.

1 mins

Guideline

British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019

The aim of the opportunistic infection guidelines is to help physicians investigate and manage people living with HIV with, or suspected of having, an opportunistic infection. They are primarily intended to guide practice in the UK and related healthcare systems.

1 min

Guideline

British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of gastrointestinal opportunistic infections 2020

Gastrointestinal (GI) symptoms occur frequently in people living with HIV. Dysphagia and diarrhoea may be caused by a wide variety of infections.

1 min

See all guidelines

Related Clinical Trials

Clinical trial

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV (CALIBRATE)

1 mins

Clinical trial

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

1 mins

Clinical trial

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

1 mins

Clinical trial

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

1 mins

Clinical trial

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

2 mins

Clinical trial

A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)

3 mins

$Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia$

Clinical trial

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

3 mins

$A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgki$

Clinical trial

A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgki

3 mins

Clinical trial

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

3 mins

Clinical trial

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)

3 mins

Clinical trial

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

3 mins

$Study of pomalidomide and low dose dexamethasone with or without pembrolizumab (MK-3475) in refractory or relapsed and refractory multiple myeloma (rrMM) (MK-3475-183/KEYNOTE-183)$

Clinical trial

Study of pomalidomide and low dose dexamethasone with or without pembrolizumab (MK-3475) in refractory or relapsed and refractory multiple myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

2 mins